Mezigdomide combined with bortezomib disrupts the cell cycle and elicits superior antitumor effects in multiple myeloma.
- DOI
- 10.1016/j.bneo.2025.100179
- Published
- 2026 Feb
- Container
- Blood neoplasia
- Publisher
- Not recorded
- Open access
- yes
Credibility signals
limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- supportingOpen access status: Normalized open-access status: open.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.1016/j.bneo.2025.100179,
title = {Mezigdomide combined with bortezomib disrupts the cell cycle and elicits superior antitumor effects in multiple myeloma.},
author = {Bjorklund CC and Larrayoz M and Kang J and Chiu H and Shtraizent N and Wu L and Li S and Hsu CC and Zhao J and Amatangelo M and Chow TT and Wollerman K and Singh RK and Sridhara S and Dudhgaonkar S and Subramanyam P and Ghosh K and Richardson PG and Bahlis NJ and Thakurta A and Martinez-Climent JA and Gandhi AK and Hagner PR},
year = {2026},
journal = {Blood neoplasia},
doi = {10.1016/j.bneo.2025.100179},
url = {https://doi.org/10.1016/j.bneo.2025.100179}
}RIS
TY - JOUR TI - Mezigdomide combined with bortezomib disrupts the cell cycle and elicits superior antitumor effects in multiple myeloma. AU - Bjorklund CC AU - Larrayoz M AU - Kang J AU - Chiu H AU - Shtraizent N AU - Wu L AU - Li S AU - Hsu CC AU - Zhao J AU - Amatangelo M AU - Chow TT AU - Wollerman K AU - Singh RK AU - Sridhara S AU - Dudhgaonkar S AU - Subramanyam P AU - Ghosh K AU - Richardson PG AU - Bahlis NJ AU - Thakurta A AU - Martinez-Climent JA AU - Gandhi AK AU - Hagner PR PY - 2026 JO - Blood neoplasia DO - 10.1016/j.bneo.2025.100179 UR - https://doi.org/10.1016/j.bneo.2025.100179 ER -
APA
CC, B., M, L., J, K., H, C., N, S., L, W., S, L., CC, H., J, Z., M, A., TT, C., K, W., RK, S., S, S., S, D., P, S., K, G., PG, R., NJ, B., A, T., JA, M., AK, G., & PR, H. (2026). Mezigdomide combined with bortezomib disrupts the cell cycle and elicits superior antitumor effects in multiple myeloma.. Blood neoplasia. https://doi.org/10.1016/j.bneo.2025.100179
Source records
- pubmed · retrieved 2026-09-26T10:34:13.295Z